Traditional and emerging risk factors for cardiovascular disease

Primary Care - Clinics in Office Practice

Volumn 32, Issue 4, 2005, Pages 963-976

  Eaton, Charles B ^a,b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A;

AGE; AIR POLLUTION; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTERY CALCIFICATION; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; COLLAGEN DISEASE; CORONARY ARTERY; DIABETES MELLITUS; DIET; ENDOTHELIUM; FAMILY HISTORY; GENDER; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; IMMOBILIZATION; INFECTION; IRON OVERLOAD; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; OBESITY; PERIODONTAL DISEASE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMALL FOR DATE INFANT; SOCIAL PSYCHOLOGY; SOCIOECONOMICS; THROMBOSIS;

AGE FACTORS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HOMOCYSTEINE; HUMANS; INCIDENCE; LIPOPROTEIN(A); METABOLIC SYNDROME X; PRIMARY HEALTH CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 28444495406     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2005.09.009     Document Type: Review

References (42)

1. D.M. Lloyd-Jones, M.G. Larson, and A. Beisner Lifetime risk of developing coronary heart disease Lancet 353 1999 89 92
2. C.B. Eaton, A.G. Bostom, and L. Yanek Family history and premature coronary heart disease J Am Board Fam Pract 9 1996 300 307
3. R.R. Williams, S.C. Hunt, and G. Heiss Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study) Am J Cardiol 87 2 2001 129 135
4. S.M. Grundy, J.I. Cleeman, and N.B. Merz Implications of recent clinical trials for the National Cholesterol Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
5. S. Yusuf, S. Hawken, and S. Ounpuu The INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
6. C. Wilhelmsson, J.A. Vedin, and D. Elmfeldt Smoking and myocardial infarction Lancet 1 1975 415 420
7. C.B. Eaton Relationship of physical activity and cardiovascular fitness to coronary heart disease, Part 1: a meta-analysis of the independent relationship of physical activity and coronary heart disease J Am Board Fam Pract 5 1992 31 42
8. C.B. Eaton, J.H. Medalie, and S.A. Flocke Self-reported physical activity predicts long-term coronary heart disease death and all-cause mortality: twenty-one year follow-up of the Israeli Ischemic Heart Disease Study Arch Fam Med 4 1995 323 329
9. C.B. Eaton, and K. Gans Cardiovascular disease and nutrition Med Health R I 83 2000 339 342
10. C.S. Fuchs, M.J. Stampfer, and G.A. Colditz Alcohol consumption and mortality among women N Engl J Med 332 1995 1245 1250
11. E.B. Rimm, E.L. Giovannucci, and W.C. Willett Prospective study of alcohol consumption and risk of coronary disease in men Lancet 338 1991 464 468
12. R.H. Eckel, D.A. York, and S. Rossner American Heart Association Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary Circulation 110 2004 2968 2975
13. E. de Groot, G.K. Hovingh, and A. Wiegman Measurement of arterial wall thickness as a surrogate marker for atherosclerosis Circulation 109 Suppl 1 2004 III33 III38
14. D.H. O'Leary, J.F. Polak, R.A. Kronmal for the Cardiovasclar Health Study Collaborative Research Group Carotid-artery intimal and medial thickness as a risk factor for myocardial infarction and stroke N Engl J Med 340 1999 14 22
15. P.W. Wilson, L.I. Kauppla, and C.J. O'Donnell Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality Circulation 103 2001 1529 1534
16. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention Circulation 108 2003 2154 2169
17. A.S. Levey, J. Coresh, and E. Balk National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
18. Go AS, G.M. Chertow, and D. Fan Chronic kidney disease and the risks of death, cardiovascular events and hospitalization N Eng J Med 351 2004 1296 1305
19. E.M. Antman, D.T. Anbe, and P.W. Armstrong AHA/ACC guidelines for the management of patients with ST-elevation myocardial infarction Circulation 110 2004 588 636
20. P.M. Ridker, R.J. Glynn, and C.H. Hennekens C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction Circulation 97 1998 2007 2011
21. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
22. M.A. Albert, E. Danielson, and N. Rifai PRINCE investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
23. P.M. Ridker, N. Rifai, and M.A. Pfeffer Cholesterol and Recurrent Events (CARE) investigators. Inflammation, pravastatin and risk of coronary events after myocardial infarction in patients with average cholesterol values Circulation 98 1998 839 844
24. P.M. Ridker, N. Rifai, and M. Clearfiled Air Force/Texas Coronary Artherosclerosis Prevention Study investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965
25. P.M. Ridker, C.P. Cannon, and D. Morrow Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 1 2005 20 28
26. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application of clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511
27. P.F. Jacques, A.G. Bostom, and P.W. Wilson Determinants of plasma total homocysteine concentration in the Framingham offspring cohort Am J Clin Nutr 73 2001 613 621
28. Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis JAMA 288 2002 2015 2022
29. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
30. J.J. Genest, J.R. McNamara, and J.M. Ordovas Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease J Am Coll Cardiol 19 1992 792 802
31. D.R. Illingworth, E.A. Stein, and Y.B. Mitchel Comparative effects of lovastatin and niacin in primary hypercholesterolemia, a prospective trial Arch Intern Med 154 1994 1586 1595
32. G.R. Thompson, V.M. Maher, and S. Matthews Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis Lancet 345 1995 811 816
33. R.S. Rosenson, C.C. Tangney, and J.M. Hafner Intraindividual variability of fibrinogen levels and cardiovascular risk profiles Arterioscler Thromb 14 1994 1928 1932
34. D.H. Solomon, E.W. Karlson, and E.B. Rimm Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 2003 1303 1307
35. J.A. Suwaidi, S. Hamasaki, and S.T. Higano Long-term follow-up of patients with midl coronary artery disease and endothelial dysfunction Circulation 101 2000 948 954
36. J. Pekkanen, A. Peters, and G. Hoek Particulate air pollution and risk of ST-segment depression during repeated submaximal exerices tests among subjects with coronary heart disease: the exposure and risk assessment of fine and ultrafine particles in ambient air (ULTRA) study Circulation 106 2002 933 938
37. Y.S. Khader, Z.S. Albashaireh, and M.A. Alomarin Periodontal diseases and the risk of coronaryheart and cerebrovascular diseases: a meta-analysis J Periodontol 75 2004 1046 1053
38. J.D. Beck, P. Eke, and G. Heiss Periodontal disease and coronary heart disease: a reappraisal of the exposure Circulation 112 2005 19 24
39. T.J. Wang, M.G. Larson, and D. Levy Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
40. G.A. Kaplan, and J.E. Keil Socioeconimic factors and cardiovascular disease: a review of the literature Circulation 88 1993 1973 1998
41. D.J.P. Barker Fetal origins of coronary heart disease BMJ 311 1995 171 174
42. P.M. Ridker, V.J. Brown, and D.E. Vaughan Established and emerging plasma biomarkers in prediction of first atherothrombotic events Circulation 109 Suppl 1 2004 IV6 IV19